Recently the mutagens of pretreated NSCLC with post-PD-1-therapy tumor cells were investigated with a loss of 7 to 18 putative mutation-associated neo-antigens in tumors of patients who acquired therapy resistance [7]. This evidence concerns the gene PDCD1 and neoplasm.